Nicholas Galakatos on why Blackstone is funding pharma's "last mile"

Blackstone wants to help close the $100 billion-a-year gap in financing late-stage clinical trials, says the private equity firm's global head of life sciences Nicholas Galakatos.

Driving the news: Blackstone closed a new $6.3 billion life sciences fund this week, its largest yet targeting late-stage drugs and technologies.